Advanced/Recurrent Endometrial Cancer
Conditions
Interventions
Observation group:This study does not involve grouping.
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years. 2.Pathologically confirmed, discharge diagnosis, or outpatient diagnosis of endometrial cancer. 3.Received or are receiving treatment at the Gynecology Oncology Center of Peking Union Medical College Hospital. 4.Have received at least one cycle of lenvatinib treatment (either as monotherapy or in combination). 5.Have available baseline imaging data and at least one follow-up record for efficacy evaluation.
Exclusion criteria
Exclusion criteria: 1.Medical records are severely incomplete, making efficacy or safety evaluation impossible. 2.Concurrent diagnosis of other active malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR;Progression-Free Survival, PFS;Disease Control Rate, DCR;Overall Survival, OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lenvatinib Starting Dose;Lenvatinib Dose Adjustments;Adverse Event Severity;Adverse Event Incidence; | — |
Countries
China
Contacts
Public ContactFan Rong
Peking Union Medical College Hospital
Outcome results
None listed